<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154605</url>
  </required_header>
  <id_info>
    <org_study_id>4666-001</org_study_id>
    <nct_id>NCT04154605</nct_id>
  </id_info>
  <brief_title>ClariFix Rhinitis RCT</brief_title>
  <acronym>CR RCT</acronym>
  <official_title>ClariFix Rhinitis Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entellus Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>North American Science Associates Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Entellus Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, sham-controlled, single-blind study of cryotherapy as a treatment for chronic&#xD;
      rhinitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multicenter, randomized, sham-controlled, single-blind (participants) study to&#xD;
      demonstrate the superiority of treatment with the ClariFix cryotherapy device for reducing&#xD;
      symptoms when compared with a sham treatment in patients with chronic rhinitis. The ClariFix&#xD;
      device is a Class II FDA-cleared medical device that is intended to be used as a cryosurgical&#xD;
      tool for the destruction of unwanted tissue during surgical procedures, including in adults&#xD;
      with chronic rhinitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized 1:1 to ClariFix or a sham procedure. After the 90-day visit, control participants may crossover to active ClariFix treatment, if they continue to meet enrollment criteria.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>All participants will be blinded to treatment assignment from procedure through their 90-day visit.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>rTNSS Responder Rate</measure>
    <time_frame>90-days post treatment</time_frame>
    <description>Responders are defined as participants with a 30% or greater reduction in reflective Total Nasal Symptom Score (rTNSS) relative to baseline. The active treatment will be compared with the sham treatment.&#xD;
The reflective Total Nasal Symptom Score (rTNSS) is a validated PRO consisting of 4 nasal symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing that are assessed over the previous 2-week period. Each symptom is rated on a scale of 0 (no symptoms) to 3 (severe symptoms) and the scores are summed to provide a total rTNSS with a possible range of 0 to 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rTNSS Responder Rate</measure>
    <time_frame>Through 12 months post treatment</time_frame>
    <description>Mean change from baseline in the rTNSS. The reflective Total Nasal Symptom Score (rTNSS) is a validated PRO consisting of 4 nasal symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing that are assessed over the previous 2-week period. Each symptom is rated on a scale of 0 (no symptoms) to 3 (severe symptoms) and the scores are summed to provide a total rTNSS with a possible range of 0 to 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total RQLQ(S)</measure>
    <time_frame>Through 12 months post treatment</time_frame>
    <description>Mean change from baseline in the Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S)) score.&#xD;
The RQLQ(S) is a validated PRO that measures functional impairments due to allergic or non-allergic rhinoconjunctivitis. The assessment consists of 28 questions related to nose symptoms, eye symptoms, non-eye/nose symptoms, sleep problems, practical problems, activity limitations, and emotional function. Each item is scored from 0 (no impairment) to 6 (severely impaired). An overall score is calculated from the mean of the 28 item responses. Domain scores are the mean of the item scores within that domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Questionnaire</measure>
    <time_frame>Through 12 months post treatment</time_frame>
    <description>Percent of participants indicating satisfaction with the procedure outcome. The satisfaction questionnaire consists of 3 questions that the participant answers at each follow-up visit. The questions indicate whether the participant is satisfied with the procedure outcome, whether the participant would undergo the procedure again for similar results, and whether the participant would recommend the procedure to family or friends with a similar condition. For each item the participant indicates agreement/disagreement with each statement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Device- and/or Procedure-related Adverse Events</measure>
    <time_frame>Through 12 months post procedure</time_frame>
    <description>The number of participants with one or more serious adverse events that are possibly, probably, or definitely related to the ClariFix device and/or procedure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Chronic Rhinitis</condition>
  <arm_group>
    <arm_group_label>ClariFix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cryotherapy of the nasal passages with the ClariFix device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham cryotherapy of the nasal passages with the ClariFix device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ClariFix cryotherapy</intervention_name>
    <description>Bilateral freeze ablation of nasal tissue using the ClariFix device.</description>
    <arm_group_label>ClariFix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham ClariFix cryotherapy</intervention_name>
    <description>Bilateral sham ablation procedure using the ClariFix device.</description>
    <arm_group_label>Sham</arm_group_label>
    <other_name>Sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be â‰¥21 years of age.&#xD;
&#xD;
          2. Has been diagnosed with chronic nonallergic or allergic rhinitis.&#xD;
&#xD;
          3. Have moderate to severe symptoms of rhinorrhea (individual reflective Total Nasal&#xD;
             Symptoms Score [rTNSS] symptom rating of 2 or 3), mild to severe symptoms of nasal&#xD;
             congestion (individual rTNSS symptom rating of 1, 2, or 3), and a minimum total rTNSS&#xD;
             of 4 (out of 12) at baseline.&#xD;
&#xD;
          4. Have an allergy test (by skin prick or intradermal testing or by validated in vitro&#xD;
             tests for specific Immunoglobin E [IgE]) on file within 12 months of the baseline&#xD;
             visit.&#xD;
&#xD;
          5. Be an appropriate candidate for bilateral ClariFix treatment performed under local&#xD;
             anesthesia.&#xD;
&#xD;
          6. Be willing and able to comply with all study elements, as indicated by their written&#xD;
             informed consent.&#xD;
&#xD;
          7. Be willing and able to comply with all study elements and provide written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have clinically significant anatomic obstructions that in the investigator's opinion&#xD;
             limit access to the posterior nose, including but not limited to severe septal&#xD;
             deviation or perforation, nasal polyps, and/or sinonasal tumor.&#xD;
&#xD;
          2. Have had previous sinus or nasal surgery within 6 months of study enrollment.&#xD;
&#xD;
          3. Have previously undergone cryotherapy or other surgical interventions for rhinitis.&#xD;
&#xD;
          4. Have an active nasal or sinus infection.&#xD;
&#xD;
          5. Have rhinitis symptoms that are primarily due to seasonal allergies.&#xD;
&#xD;
          6. Have plans to (or otherwise anticipates the need to) undergo an ENT (ear, nose,&#xD;
             throat) procedure concurrently or within 3 months after the study procedure.&#xD;
&#xD;
          7. Is on prescribed anticoagulants (eg, warfarin, Plavix) or 325 mg aspirin that cannot&#xD;
             be discontinued before the procedure (81 mg aspirin and herbal supplements are&#xD;
             acceptable).&#xD;
&#xD;
          8. Be unable to discontinue ipratropium bromide (IB) at least 14 days before baseline and&#xD;
             through the 90-day follow-up visit.&#xD;
&#xD;
          9. Have a history of chronic epistaxis or experienced a significant epistaxis event&#xD;
             (defined as epistaxis requiring medical intervention) in the past 3 months.&#xD;
&#xD;
         10. Have a history of rhinitis medicamentosa.&#xD;
&#xD;
         11. Have had previous head and/or neck irradiation.&#xD;
&#xD;
         12. Have an allergy or intolerance to local anesthetic agents.&#xD;
&#xD;
         13. Have cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud's&#xD;
             disease, and/or open and/or infected wounds at or near the target tissue.&#xD;
&#xD;
         14. Have a neurological, medical, psychiatric condition, or social circumstance that would&#xD;
             potentially increase risk, interfere with study participation, or confound&#xD;
             interpretation of study data.&#xD;
&#xD;
         15. Be participating in another clinical research study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony DelSignore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ichan School of Medicine, Mount Sinai, New York, NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ENT Associates of South Florida</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <results_first_submitted>August 24, 2021</results_first_submitted>
  <results_first_submitted_qc>August 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2021</results_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cryotherapy</keyword>
  <keyword>Cryoablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT04154605/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ClariFix</title>
          <description>Cryotherapy of the nasal passages with the ClariFix device.&#xD;
ClariFix cryotherapy: Bilateral freeze ablation of nasal tissue using the ClariFix device.</description>
        </group>
        <group group_id="P2">
          <title>Sham</title>
          <description>Sham cryotherapy of the nasal passages with the ClariFix device&#xD;
Sham ClariFix cryotherapy: Bilateral sham ablation procedure using the ClariFix device.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Procedure Canceled</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed follow up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ClariFix</title>
          <description>Cryotherapy of the nasal passages with the ClariFix device.&#xD;
ClariFix cryotherapy: Bilateral freeze ablation of nasal tissue using the ClariFix device.</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>Sham cryotherapy of the nasal passages with the ClariFix device&#xD;
Sham ClariFix cryotherapy: Bilateral sham ablation procedure using the ClariFix device.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="133"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="15.8"/>
                    <measurement group_id="B2" value="58.3" spread="16.4"/>
                    <measurement group_id="B3" value="55.2" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of rhinitis (nonallergic rhinitis)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>rTNSS Responder Rate</title>
        <description>Responders are defined as participants with a 30% or greater reduction in reflective Total Nasal Symptom Score (rTNSS) relative to baseline. The active treatment will be compared with the sham treatment.&#xD;
The reflective Total Nasal Symptom Score (rTNSS) is a validated PRO consisting of 4 nasal symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing that are assessed over the previous 2-week period. Each symptom is rated on a scale of 0 (no symptoms) to 3 (severe symptoms) and the scores are summed to provide a total rTNSS with a possible range of 0 to 12.</description>
        <time_frame>90-days post treatment</time_frame>
        <population>1active ClariFix arm participant returned for the follow up visit, but did not complete the rTNSS</population>
        <group_list>
          <group group_id="O1">
            <title>ClariFix</title>
            <description>Cryotherapy of the nasal passages with the ClariFix device.&#xD;
ClariFix cryotherapy: Bilateral freeze ablation of nasal tissue using the ClariFix device.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham cryotherapy of the nasal passages with the ClariFix device&#xD;
Sham ClariFix cryotherapy: Bilateral sham ablation procedure using the ClariFix device.</description>
          </group>
        </group_list>
        <measure>
          <title>rTNSS Responder Rate</title>
          <description>Responders are defined as participants with a 30% or greater reduction in reflective Total Nasal Symptom Score (rTNSS) relative to baseline. The active treatment will be compared with the sham treatment.&#xD;
The reflective Total Nasal Symptom Score (rTNSS) is a validated PRO consisting of 4 nasal symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing that are assessed over the previous 2-week period. Each symptom is rated on a scale of 0 (no symptoms) to 3 (severe symptoms) and the scores are summed to provide a total rTNSS with a possible range of 0 to 12.</description>
          <population>1active ClariFix arm participant returned for the follow up visit, but did not complete the rTNSS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>rTNSS Responder Rate</title>
        <description>Mean change from baseline in the rTNSS. The reflective Total Nasal Symptom Score (rTNSS) is a validated PRO consisting of 4 nasal symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing that are assessed over the previous 2-week period. Each symptom is rated on a scale of 0 (no symptoms) to 3 (severe symptoms) and the scores are summed to provide a total rTNSS with a possible range of 0 to 12.</description>
        <time_frame>Through 12 months post treatment</time_frame>
        <posting_date>07/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total RQLQ(S)</title>
        <description>Mean change from baseline in the Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S)) score.&#xD;
The RQLQ(S) is a validated PRO that measures functional impairments due to allergic or non-allergic rhinoconjunctivitis. The assessment consists of 28 questions related to nose symptoms, eye symptoms, non-eye/nose symptoms, sleep problems, practical problems, activity limitations, and emotional function. Each item is scored from 0 (no impairment) to 6 (severely impaired). An overall score is calculated from the mean of the 28 item responses. Domain scores are the mean of the item scores within that domain.</description>
        <time_frame>Through 12 months post treatment</time_frame>
        <posting_date>07/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction Questionnaire</title>
        <description>Percent of participants indicating satisfaction with the procedure outcome. The satisfaction questionnaire consists of 3 questions that the participant answers at each follow-up visit. The questions indicate whether the participant is satisfied with the procedure outcome, whether the participant would undergo the procedure again for similar results, and whether the participant would recommend the procedure to family or friends with a similar condition. For each item the participant indicates agreement/disagreement with each statement.</description>
        <time_frame>Through 12 months post treatment</time_frame>
        <posting_date>07/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Device- and/or Procedure-related Adverse Events</title>
        <description>The number of participants with one or more serious adverse events that are possibly, probably, or definitely related to the ClariFix device and/or procedure.</description>
        <time_frame>Through 12 months post procedure</time_frame>
        <posting_date>07/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening through 90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ClariFix</title>
          <description>Cryotherapy of the nasal passages with the ClariFix device.&#xD;
ClariFix cryotherapy: Bilateral freeze ablation of nasal tissue using the ClariFix device.</description>
        </group>
        <group group_id="E2">
          <title>Sham</title>
          <description>Sham cryotherapy of the nasal passages with the ClariFix device&#xD;
Sham ClariFix cryotherapy: Bilateral sham ablation procedure using the ClariFix device.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pain/discomfort at treatment site</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="68"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study follow up is ongoing. Only 90 day endpoints are available currently.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robyn Schacherer, Manager Clinical Affairs</name_or_title>
      <organization>Stryker</organization>
      <phone>763-463-7054</phone>
      <email>robyn.schacherer@stryker.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

